This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/domain/vavai/projekt/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n15http://linked.opendata.cz/ontology/domain/vavai/
n21http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n7http://bibframe.org/vocab/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F13%3A10191810%21RIV14-MZ0-00064165/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F13%3A10191810%21RIV14-MZ0-00064165
rdf:type
n15:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1016/j.jneuroim.2013.07.010
dcterms:description
Objectives: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). Methods: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months after start of interferon-beta treatment Results: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1 +/- SD 8.1 years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C (p = 0.009) and TC (p = 0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse (p = 0.006) and the greater number of relapses (p = 0.009) in patients with high HDL-C. Anti-EBV VCA antibody levels were associated with greater number of new 12 lesions (p = 0.002) and with increased brain atrophy (p < 0.001) in patients with high LDL-C. Conclusions: Our results indicate that higher levels of anti-EBV EBNA-1 antibodies are associated with higher LDL-C and TC levels. Anti-CMV positive individuals have greater disease progression in the presence of higher HDL-C levels. Individuals with higher levels of anti-EBV VCA antibodies have greater progression on MRI measures in the presence of higher LDL-C. Objectives: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). Methods: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months after start of interferon-beta treatment Results: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1 +/- SD 8.1 years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C (p = 0.009) and TC (p = 0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse (p = 0.006) and the greater number of relapses (p = 0.009) in patients with high HDL-C. Anti-EBV VCA antibody levels were associated with greater number of new 12 lesions (p = 0.002) and with increased brain atrophy (p < 0.001) in patients with high LDL-C. Conclusions: Our results indicate that higher levels of anti-EBV EBNA-1 antibodies are associated with higher LDL-C and TC levels. Anti-CMV positive individuals have greater disease progression in the presence of higher HDL-C levels. Individuals with higher levels of anti-EBV VCA antibodies have greater progression on MRI measures in the presence of higher LDL-C.
dcterms:title
Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes
skos:prefLabel
Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes
skos:notation
RIV/00064165:_____/13:10191810!RIV14-MZ0-00064165
n15:predkladatel
n16:ico%3A00064165
n3:aktivita
n8:Z n8:I n8:P
n3:aktivity
I, P(NT13237), Z(MSM0021620849)
n3:cisloPeriodika
1-2
n3:dodaniDat
n13:2014
n3:domaciTvurceVysledku
n4:4511042 n4:6253393 n4:8441456 n4:6857108 n4:8309213 n4:8895465
n3:druhVysledku
n19:J
n3:duvernostUdaju
n10:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
80669
n3:idVysledku
RIV/00064165:_____/13:10191810
n3:jazykVysledku
n20:eng
n3:klicovaSlova
Clinically isolated syndromes; Multiple sclerosis; Environmental factor interactions; Epstein-Barr virus; Cholesterol; Lipid
n3:klicoveSlovo
n11:Clinically%20isolated%20syndromes n11:Multiple%20sclerosis n11:Cholesterol n11:Environmental%20factor%20interactions n11:Lipid n11:Epstein-Barr%20virus
n3:kodStatuVydavatele
NL - Nizozemsko
n3:kontrolniKodProRIV
[16F493AF7659]
n3:nazevZdroje
Journal of Neuroimmunology
n3:obor
n9:FH
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
14
n3:projekt
n12:NT13237
n3:rokUplatneniVysledku
n13:2013
n3:svazekPeriodika
263
n3:tvurceVysledku
Ramanathan, Murali Badgett, Darlene Vaněčková, Manuela Seidl, Zdeněk Havrdová, Eva Týblová, Michaela Bergsland, Niels Hagemeier, Jesper Weinstock-Guttman, Bianca Tamano-Blanco, Miriam Krásenský, Jan Zivadinov, Robert Horáková, Dana Ramasamy, Deepa P.
n3:wos
000326258200016
n3:zamer
n21:MSM0021620849
s:issn
0165-5728
s:numberOfPages
7
n7:doi
10.1016/j.jneuroim.2013.07.010